Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144886 | 1.00 | HTT (0.62) | HTTKDM4EMEN1KMT2ASMN1; SMN2 | |
| Water SCHEMBL11591334 | 0.98 | HTT (0.61) | HTTKDM4EMEN1KMT2ASMN1; SMN2 | |
| Chlorobenzene SCHEMBL28114087 | 0.81 | TSHR (0.48) | HTTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6810853 | 0.79 | KDM4E (0.57) | HTTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4375606 | 0.78 | PARP1 (0.56) | HTTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7622154 | 0.78 | KMT2A (0.47) | HTTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3096979 | 0.78 | PARP1 (0.56) | HTTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8661356 | 0.78 | KMT2A (0.47) | HTTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10813945 | 0.77 | PARP1 (0.52) | HTTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10813941 | 0.77 | PARP1 (0.52) | HTTKDM4EMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110294758-A | 2- replaces 5,6- dihydro-pyrazolo [5,1- α] isoquinolin, derivative and its synthetic method | 湘潭大学 | 2019-10-01 | — | — | CN | claimed |
| CN-109705146-A | 2- amino benzo [4,5] thieno [3,2-d] thiazole, derivative and its synthetic method | 湘潭大学 | 2019-05-03 | — | — | CN | claimed |
| CN-118440019-A | Triazinyl diketone oxime ester compound and preparation method and application thereof | 湖南省农业生物技术研究所 | 2024-08-06 | — | — | CN | disclosed |
| CN-110294758-A | 2- replaces 5,6- dihydro-pyrazolo [5,1- α] isoquinolin, derivative and its synthetic method | 湘潭大学 | 2019-10-01 | — | — | CN | disclosed |
| CN-109705146-A | 2- amino benzo [4,5] thieno [3,2-d] thiazole, derivative and its synthetic method | 湘潭大学 | 2019-05-03 | — | — | CN | disclosed |
| EP-2927218-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| CN-106146350-B | A kind of new method of synthesizing amino formic acid oxime ester derivative | 华南理工大学 | 2017-10-20 | — | — | CN | disclosed |
| US-9725423-B2 | Tetrazolinone compound and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| CN-106146350-A | A kind of new method of synthesizing amino methylcarbamoyl oximino ester derivant | 华南理工大学 | 2016-11-23 | — | — | CN | disclosed |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2927218-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | disclosed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | disclosed |
| US-20060270687-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-11-30 | — | — | US | disclosed |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-10-26 | — | — | US | disclosed |
| US-7122550-B2 | Protein kinase inhibitors | CYTOPIA PTY LTD (AU) | 2006-10-17 | — | — | US | disclosed |
| US-20060148824-A1 | Protein kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2006-07-06 | — | — | US | disclosed |
| US-20050004140-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2005-01-06 | — | — | US | disclosed |
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2004-11-25 | — | — | US | disclosed |
| US-4124227-A | Oxime ethers of Michler's hydrol, method of producing same and pressure-sensitive recording systems containing such compounds | MOORE BUSINESS FORMS, INC. (US) | 1978-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | LCK, IRAK1, MAP2K5 | HTT 4187/4885KDM4E 2692/4885MEN1 1677/4885 |
| US-20060270687-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | HTT 2541/4885KDM4E 1738/4885MEN1 889/4885 |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | MAP4K2, MAP4K5, MAP4K4 | HTT 1397/4885KDM4E 1505/4885MEN1 753/4885 |
| US-20050004140-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | HTT 2541/4885KDM4E 1738/4885MEN1 889/4885 |
| US-20060148824-A1 | Protein kinase inhibitors | MAP3K20, MAP4K2, MAP3K1 | HTT 3975/4885KDM4E 1981/4885MEN1 1877/4885 |
| US-20070161635-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K10 | HTT 2135/4885KDM4E 2364/4885MEN1 1251/4885 |
| US-20150299146-A1 | TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF | RTN3, CYCS, ATL3 | HTT 1492/4885KDM4E 2748/4885MEN1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.